ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe (ACCESS-EU)
|Mitral Valve (MV) Regurgitation||Device: MitraClip Drug: Medical Management Procedure: Mitral Valve Surgery|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe|
- Change from Baseline in Quality of Life at 12-month follow-up. [ Time Frame: 12 months ]Minnesota Living with Heart Failure Questionnaire will be used as a measure of the patients' perceptions of the effects of congestive heart failure on their lives.
- Change from baseline in 6-minute walk distance test at 12 months. [ Time Frame: 12 months ]The 6-minute walk distance test will be used to measure the patient's exercise capacity.
|Study Start Date:||October 2008|
|Study Completion Date:||August 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
Patients treated with the MitraClip System.
The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
Patients with MR managed non-surgically based on standard hospital clinical practice.
Drug: Medical Management
The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
Mitral Valve Surgery
Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
Procedure: Mitral Valve Surgery
The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
The primary objective of ACCESS-EU Phase I is to gain information in the European Union Countries regarding the use of the MitraClip System with respect to health economics and clinical care.
PHASE II: (HAS BEEN CLOSED BY SPONSOR) The primary objective of ACCESS-EU Phase II is to gather additional clinical data, specifically Echocardiography Core Laboratory measurements of MR severity and left ventricular volumes and diameters, and other echocardiographic measures, on patients undergoing the MitraClip procedure in the European Union Countries,
Clinical data collected from both study phases, is expected to contribute to decision making with regards to MitraClip therapy selection in patients with MR: (a) by establishing the value of the MitraClip therapy in the continuum of care; and (b) by providing practical information that will allow physicians to make therapeutic decisions, assist hospitals to make purchasing decisions, and assist insurers in making coverage decisions.
ACCESS-Europe is a two-phase prospective, observational, multicenter post-approval study of the MitraClip System for the treatment of mitral regurgitation (MR) in the European Union Countries. Patients will be evaluated per standard practice at baseline, discharge, 6-Months and 12-Months.
Phase I of the study consists of patients who receive the MitraClip system for the treatment of MR and two concurrent comparator groups of (a) medically managed heart failure patients with MR and (b) patients who have undergone mitral valve surgery for MR. The two comparator groups will be followed and evaluated primarily from a health economic perspective.
ACCESS EU Study Phase II will consist of only patients who receive the MitraClip System, with the objective to collect additional clinical data, specifically Echocardiography Core Laboratory evaluation of MR severity and other echocardiographic measures.
Enrollment of patients in each study phase is as follows:
ACCESS-EU PHASE I:
- A minimum of 300 MitraClip Therapy group patients,
- A minimum of 100 patients in the Mitral Valve Surgery comparator group
- As many patients as possible in the Medical Therapy comparator group
First Patient Enrollment Projection: Q1, 2009 Last Patient Enrollment Projection: Enrollment in the Mitral Valve Surgery and Medically Therapy groups ceased on December 31, 2010. Enrollment in the MitraClip group will cease when Phase II of the study is initiated at each site.
ACCESS-EU PHASE II:
A minimum of 300 MitraClip therapy subjects will be enrolled in Phase II.
First Patient Enrollment Projection: Q2, 2011 Last Patient Enrollment Projection: Enrollment will cease when the Sponsor has determined that an adequate number of patients have been enrolled.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01288976
|Gottingen, Germany, 37075|
|Study Director:||Barathi Sethuraman, PhD||Abbott Vascular Structural Heart (Evalve Inc)|
|Principal Investigator:||Wolfgang Schillinger, MD||Universitatsmedizin Gottingen|
|Principal Investigator:||Francesco Maisano, MD||Fondazion Ctr San Raffaele Del Monte Tabor Istituto|